KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) EBT Margin (2020 - 2023)

AbCellera Biologics (ABCL) has disclosed EBT Margin for 4 consecutive years, with 529.49% as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, EBT Margin fell 38369.0% year-over-year to 529.49%, compared with a TTM value of 457.67% through Dec 2023, down 50693.0%, and an annual FY2024 reading of 695.02%, down 23735.0% over the prior year.
  • EBT Margin was 529.49% for Q4 2023 at AbCellera Biologics, up from 595.27% in the prior quarter.
  • Across five years, EBT Margin topped out at 79.65% in Q1 2021 and bottomed at 595.27% in Q3 2023.
  • Average EBT Margin over 4 years is 137.28%, with a median of 21.88% recorded in 2020.
  • The sharpest move saw EBT Margin surged 49938bps in 2022, then plummeted -64122bps in 2023.
  • Year by year, EBT Margin stood at 77.52% in 2020, then dropped by -22bps to 60.8% in 2021, then plummeted by -340bps to 145.8% in 2022, then plummeted by -263bps to 529.49% in 2023.
  • Business Quant data shows EBT Margin for ABCL at 529.49% in Q4 2023, 595.27% in Q3 2023, and 377.91% in Q2 2023.